Solensia represents a breakthrough in feline healthcare, offering a revolutionary solution for the management of feline osteoarthritis (OA) pain through a once-monthly injectable monoclonal antibody therapy. This innovative treatment is designed to effectively control the debilitating pain associated with OA in cats, ultimately enhancing their overall mobility, comfort, and well-being. In a comprehensive 3-month study, a remarkable 77% of cat owners reported significant improvements in the signs of pain when their feline companions were treated with Solensia on a monthly basis. Notably, the therapy demonstrated an exceptional level of tolerability in field studies that included cats at various stages of renal impairment, specifically those identified as IRIS stage 1 or 2. Solensia emerges as a promising and well-received solution, marking a significant stride towards improving the quality of life for cats grappling with the challenges of osteoarthritis.
Introducing the product Librela . Assisting dog owners in understanding and managing their canine companions’ osteoarthritis (OA) pain is crucial for enhancing the well-being of our furry friends. Recognizing OA pain in dogs can be challenging for pet owners, with nearly 40% of dogs displaying signs of discomfort, yet less than half receiving a formal diagnosis. To bridge this gap in awareness, the resources provided on this page aim to educate dog owners about OA and its impact on their pets. Introducing them to Librela, a potential solution for managing OA pain in dogs, these materials serve as valuable tools in preparing pet owners for informed discussions during follow-up appointments. It is essential to empower dog owners with knowledge, enabling them to proactively address and mitigate the effects of OA on their beloved canine companions. Additionally, highlighting that dogs treated with nonsteroidal anti-inflammatory drugs (NSAIDs) for OA pain receive approximately 60.5 days of therapy annually emphasizes the importance of early detection and intervention.